Conference Coverage

ASCO 2015 Complete Coverage

Bortezomib Consolidation More Effective Than Observation for Newly Diagnosed Multiple Myeloma

Bortezomib Consolidation More Effective Than Observation for Newly Diagnosed Multiple Myeloma

Bortezomib consolidation significantly improved progression-free survival compared with observation in multiple myeloma.

Daratumumab Provides Durable Activity in Heavily Pre-Treated Multiple Myeloma

Daratumumab Provides Durable Activity in Heavily Pre-Treated Multiple Myeloma

Daratumumab demonstrated profound durable activity with meaningful responses in patients with heavily pretreated multiple myeloma.

Temozolomide with Radiotherapy Safer, Equally Effective as Nitrosureas for Anaplastic Astrocytoma

Temozolomide with Radiotherapy Safer, Equally Effective as Nitrosureas for Anaplastic Astrocytoma

Radiotherapy plus temozolomide did not appear to significantly improve survival for anapestic astrocytoma compared with nitrosurea.

Efficacy of Chemotherapy Similar to Radiotherapy for Anaplastic Glioma

Efficacy of Chemotherapy Similar to Radiotherapy for Anaplastic Glioma

Long-term data do not support efficacy of primary temozolomide monotherapy versus radiotherapy in anapestic glioma.

Tumor Treating Fields Improve Survival in Newly Diagnosed Glioblastoma

Tumor Treating Fields Improve Survival in Newly Diagnosed Glioblastoma

Tumor Treating Fields improved progression-free survival and overall survival in patients with newly diagnosed glioblastoma.

Worse Outcomes in Patients Managed Without Radiotherapy After Chemo for Breast Cancer

Worse Outcomes in Patients Managed Without Radiotherapy After Chemo for Breast Cancer

Patients managed without radiotherapy after neoadjuvant chemotherapy for breast cancer have a significantly worse outcome.

Etirinotecan Pegol Benefits Patients with Advanced Breast Cancer

Etirinotecan Pegol Benefits Patients with Advanced Breast Cancer

Etirinotecan pegol provided a clinically meaningful benefit to patients with late-stage advanced breast cancer.

Pembrolizumab Immunotherapy Effective in Recurrent, Metastatic Head and Neck Cancer

Pembrolizumab Immunotherapy Effective in Recurrent, Metastatic Head and Neck Cancer

Pembrolizumab immunotherapy is effective in recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).

Panitumumab, Accelerated Fractionation RX Not Superior to Standard of Care in Head and Neck Cancer

Panitumumab, Accelerated Fractionation RX Not Superior to Standard of Care in Head and Neck Cancer

Panitumumab plus accelerated fractionation radiotherapy (AFX) was not superior in squamous cell carcinoma of the head and neck.

Complete Response Rate at 30 Months Correlates with Progression-Free Survival in Follicular Lymphoma

Complete Response Rate at 30 Months Correlates with Progression-Free Survival in Follicular Lymphoma

Complete response rate at 30 months is a surrogate endpoint for progression-free survival in first-line follicular lymphoma trials.

Neratinib Improves Two-Year Survival in Breast Cancer After Adjuvant Chemo, Trastuzumab

Neratinib Improves Two-Year Survival in Breast Cancer After Adjuvant Chemo, Trastuzumab

Patients with HER2-positive early-stage breast cancer who received neratinib had improved invasive and ductal carcinoma in situ (DCIS) survival.

Palbociclib, Fulvestrant Improves Progression-Free Survival in HR+, HER2- Breast Cancer

Palbociclib, Fulvestrant Improves Progression-Free Survival in HR+, HER2- Breast Cancer

Palbociclib with fulvestrant improved progression-free survival in hormone receptor-positive, HER2-negative advanced breast cancer.

Denosumab Significantly Reduces Fractures in Postmenopausal Women with Breast Cancer

Denosumab Significantly Reduces Fractures in Postmenopausal Women with Breast Cancer

Denosumab significantly reduced fractures in postmenopausal women with breast cancer receiving aromatase inhibitors (AIs).

Polatuzumab Plus Rituximab May Be Safe, Effective for Follicular Lymphoma

Polatuzumab Plus Rituximab May Be Safe, Effective for Follicular Lymphoma

Polatuzumab plus rituximab in relapsed/refractory follicular lymphoma showed high overall response rates.

Obinutuzumab Plus Bendamustine Improves Progression-Free Survival in Non-Hodgkin Lymphoma

Obinutuzumab Plus Bendamustine Improves Progression-Free Survival in Non-Hodgkin Lymphoma

Obinutuzumab combined with bendamustine improved progression-free survival in rituximab-refractory indolent non-Hodgkin lymphoma (iNHL).

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs